A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

IsraelRecruitingPHASE2

Conditions

Multiple System Atrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Teva Investigational Site 15554, La Jolla, California, United States

  • Teva Investigational Site 15545, Los Angeles, California, United States

  • Teva Investigational Site 15547, Washington D.C., District of Columbia, United States

  • Teva Investigational Site 15544, Boca Raton, Florida, United States

  • Teva Investigational Site 15555, Tampa, Florida, United States

  • Teva Investigational Site 15550, Chicago, Illinois, United States

  • Teva Investigational Site 15546, Kansas City, Kansas, United States

  • Teva Investigational Site 15736, Boston, Massachusetts, United States

  • Teva Investigational Site 15870, Farmington Hills, Michigan, United States

  • Teva Investigational Site 15552, Rochester, Minnesota, United States

  • Teva Investigational Site 15549, New York, New York, United States

  • Teva Investigational Site 15551, New York, New York, United States

  • Teva Investigational Site 15553, Durham, North Carolina, United States

  • Teva Investigational Site 15735, Hershey, Pennsylvania, United States

  • Teva Investigational Site 15548, Pittsburgh, Pennsylvania, United States

  • Teva Investigational Site 15869, Georgetown, Texas, United States

  • Teva Investigational Site 15873, Alexandria, Virginia, United States

  • Teva Investigational Site 15543, Spokane, Washington, United States

  • Teva Investigational Site 35290, Bordeaux, France

  • Teva Investigational Site 35289, Marseille, France

  • Teva Investigational Site 35291, Salpêtrière, France

  • Teva Investigational Site 35292, Toulouse, France

  • Teva Investigational Site 32823, Beelitz-Heilstätten, Germany

  • Teva Investigational Site 32818, Dresden, Germany

  • Teva Investigational Site 32822, Düsseldorf, Germany

  • Teva Investigational Site 32825, Kassel, Germany

  • Teva Investigational Site 32826, Leipzig, Germany

  • Teva Investigational Site 32824, Marburg, Germany

  • Teva Investigational Site 32820, München, Germany

  • Teva Investigational Site 32819, Münster, Germany

  • Teva Investigational Site 32821, Ulm, Germany

  • Teva Investigational Site 80203, Haifa, Israel

  • Teva Investigational Site 80215, Jerusalem, Israel

  • Teva Investigational Site 80204, Tel Aviv, Israel

  • Teva Investigational Site 30299, Bologna, Italy

  • Teva Investigational Site 30297, Catania, Italy

  • Teva Investigational Site 30298, Milan, Italy

  • Teva Investigational Site 30294, Padova, Italy

  • Teva Investigational Site 30296, Roma, Italy

  • Teva Investigational Site 30295, Salerno, Italy

  • Teva Investigational Site 84140, Chiba, Japan

  • Teva Investigational Site 84139, Fuchū, Japan

  • Teva Investigational Site 84136, Gifu, Japan

  • Teva Investigational Site 84137, Niigata, Japan

  • Teva Investigational Site 84138, Sagamihara, Japan

  • Teva Investigational Site 84141, Sanda-shi, Japan

  • Teva Investigational Site 84135, Sendai, Japan

  • Teva Investigational Site 31323, Barcelona, Spain

  • Teva Investigational Site 31321, Barcelona, Spain

  • Teva Investigational Site 31324, Barcelona, Spain

  • Teva Investigational Site 31327, Madrid, Spain

  • Teva Investigational Site 31320, Pamplona, Spain

  • Teva Investigational Site 31322, Seville, Spain

  • Teva Investigational Site 31319, Valencia, Spain

Study leads
  • Tev Medical Expert, Study Director

    Study Director

    Teva Branded Pharmaceutical Products R&D LLC